2020 Guide to Patient Support Services

Novartis Oncology

  • Novartis Patient Assistance Now Oncology
  • 800-245-5356
  • VISIT WEBSITE

Novartis Oncology provides a full range of patient assistance programs and support services through Novartis Patient Assistance Now Oncology (PANO). This comprehensive support program provides support and resources for patients and providers through the Novartis Oncology Universal Co-pay Program, Novartis Patient Assistance Foundation.

In addition, drug-specific programs are available for some of Novartis Oncology’s medications, including Kisqali Care, Kymriah Cares, and Rydapt NOW.

The list of Novartis Oncology medicines, their indications, and their respective support programs is provided in the Table.

The Novartis PANO platform is a comprehensive oncology resource that provides information on patient assistance, including reimbursement and support programs. These support options include insurance verification, education on Medicare, and information about financial assistance and free medication programs. Click here for more information about accessing support.

Novartis Patient Assistance Foundation

Patients with financial hardship who have no third-party insurance coverage for their Novartis medicines may be eligible to receive the drugs at no cost.

Novartis Oncology Universal Co-Pay Program

Patients with commercial insurance or patients paying cash without government-funded insurance may be eligible for copay assistance.

Providers can visit HCP.Novartis.com/access or call 800-282-7630 for assistance with the reimbursement process for Novartis Oncology drugs.

Services include insurance benefits and coverage verification, copayment clarifications, assistance with coding and billing questions, denials and appeals support, as well as alternative funding searches and referrals to Novartis Oncology brand-specific copay card programs and independent assistance programs.

Kisqali Care

This comprehensive patient support program provides access to Kisqali (ribociclib) tablets for patients with commercial insurance who are prescribed Kisqali.

Kymriah Cares

For patients who are prescribed Kymriah (tisagenlecleucel), Kymriah Cares provides information on financial assistance and patient support programs, including insurance coverage, and offers resources to help throughout treatment.

Rydapt NOW

This program provides support to patients who are prescribed Rydapt (midostaurin) capsules. Care coordinators provide patients access to a clinical educator and information about financial assistance.

ELIGIBILITY

Patients looking for financial assistance for a Novartis Oncology medication can visit Patient.Novartis­Oncology.com/financial-assistance to check their eligibility based on their insurance status.

Novartis Oncology Universal Co-Pay Program

The enrollment requirements for this drug-specific program vary by medication. To enroll in a specific drug program, visit Copay.Novartisoncology.com and select the prescribed medication, or call 877-577-7756.

To be eligible for the Novartis Oncology Universal Co-pay Program, patients must:

  • Have commercial insurance; those with federally funded insurance are not eligible
  • Be a resident of the United States and have a qualified Novartis medication prescribed for an approved indication.

Eligible patients may pay up to $25 monthly out of pocket, depending on the medication, with a maximum annual benefit of $15,000 for medications.

Gleevec $10 Co-Pay

Patients with commercial insurance who are prescribed Gleevec (imatinib mesylate) may be eligible for the Novartis Oncology Universal Co-pay Program. Eligible patients may pay the first $10 for a 30-day supply of Gleevec, and the program will pay ≤$10,630 for a 30-day supply, with an annual maximum of $30,000.

Kisqali Care

Commercially insured patients who are experiencing coverage delays for Kisqali may be eligible for the Kisqali 5-Treatment Cycle Access Program, which provides:

  • ≤5 free treatment cycles of Kisqali
  • A voucher for 1 free treatment cycle of Kisqali, available at FreeTreatmentVoucher.com or by calling 800-282-7630
  • Educational information about

Kisqali, insurance coverage, and financial assistance, as well as access to a dedicated navigator who will provide one-on-one assistance.

Rydapt NOW

Patients who have been prescribed Rydapt for an FDA-approved indication and are new to therapy or are experiencing insurance coverage delay may be eligible to receive a 14-day supply of Rydapt through the Rydapt NOW Access Program or the Rydapt NOW Free Supply Program. Rydapt NOW also provides eligible patients access to Care Coordinators who will provide help in investigating the patient benefits about access to Rydapt, and help with insurance verification, prior authorizations, and finding a pharmacy in their health plan.

Tasigna 1 Month Free Trial Voucher

Eligible patients with a valid prescription for Tasigna (nilotinib) may be able to receive 1 month of medication for free by using the Tasigna Free Trial Voucher.

Novartis Patient Assistance Foundation

Patients who are experiencing financial hardship and have limited or no public or private prescription coverage may be able to receive Novartis Oncology medication for free through this foundation.

To be eligible for this program, the patient must:

  • Be a citizen of the United States
  • Have proof of income that meets financial eligibility requirements
  • Have limited or no prescription coverage.

APPLICATION & ENROLLMENT

Novartis Oncology Universal Co-pay Program

Enrollment for copay assistance is also medication-specific. In some cases, a copay card can be downloaded and printed from the drug’s website; for some drugs, patients may be required to complete a copay assistance enrollment form and provide it to the specialty pharmacy.

Novartis Patient Assistance Foundation

The enrollment process varies by medication. Click here to learn more about the application process for a specific prescribed medication, visit or call 800-277-2254.

By selecting the medication from the list, applicants can access enrollment information that is specific to the particular drug.

TABLE NOVARTIS ONCOLOGY/SUPPORTIVE CARE DRUGS

Drugs
Indications
Patient support programs

Drug
Afinitor (everolimus) tablets/Afinitor Disperz (everolimus suspension)
Indications
Advanced HR-positive, HER2-negative breast cancer; advanced kidney cancer; advanced neuroendocrine tumors of gastrointestinal or lung origin; renal angiomyolipoma with TSC; subependymal giant-cell astrocytoma with TSC
Patient support programs

Drug
Arzerra (ofatumumab)
Indications
Recurrent or progressive chronic lymphocytic leukemia
Patient support program

Drug
Exjade (deferasirox)
Indications
Chronic iron overload caused by blood transfusions
Patient support programs

Drug
Gleevec (imatinib mesylate)
Indications
Ph+ chronic myeloid leukemia; Ph+ acute lymphoblastic leukemia; myelodysplastic or myeloproliferative diseases; aggressive systemic mastocytosis; hypereosinophilic syndrome and/or chronic eosinophilic leukemia; unresectable, recurrent, and/or metastatic dermatofibrosarcoma protuberans; CD117-positive unresectable and/or metastatic malignant gastrointestinal stromal tumors
Patient support programs

Drug
Hycamtin (topotecan) capsules
Indications
Relapsed small-cell lung cancer
Patient support program

Drug
Hycamtin (topotecan hydrochloride) for injection
Indications
Metastatic carcinoma of the ovary; small-cell lung cancer; recurrent or persistent carcinoma of the cervix
Patient support program

Drug
Jadenu (deferasirox) tablets
Indications
Chronic iron overload caused by blood transfusions
Patient support programs

Drug
Kisqali (ribociclib) tablets
Indications
HR-positive, HER2-negative advanced or metastatic breast cancer, as initial endocrine-based therapy, in combination with an aromatase inhibitor; postmenopausal women with HR-positive, HER2-negative advanced or metastatic breast cancer, as initial endocrine-based therapy or after disease progression on endocrine therapy, in combination with fulvestrant
Patient support programs

Drug
Kymriah (tisagenlecleucel)
Indications
Patients aged ≤25 years with relapsed or refractory B-cell precursor acute lymphoblastic leukemia; adults with relapsed or refractory diffuse large B-cell lymphoma after ≥2 lines of systemic therapy
Patient support program

Drug
Mekinist (trametinib)
Indications
Patient support programs

Drug
Piqray (alpelisib)
Indications
Treatment, in combination with fulvestrant, of postmenopausal women, and men, with HR-positive, HER2-negative, advanced or metastatic breast cancer and PIK3CA mutation, as detected by an FDA-approved test, that is progressing during or after an endocrine-based regimen
Patient support programs

Drug
Promacta (eltrombopag)
Indications
Chronic immune (idiopathic) thrombocytopenia; severe aplastic anemia
Patient support programs

Drug
Rydapt (midostaurin) capsules
Indications
Newly diagnosed acute myeloid leukemia with FLT3 mutation, in combination with cytarabine and daunorubicin induction and cytarabine consolidation; aggressive systemic mastocytosis, systemic mastocytosis with hematologic neoplasm, or mast-cell leukemia
Patient support programs

Drug
Sandostatin LAR Depot (octreotide acetate for injectable suspension)
Indications
Severe diarrhea or flushing episodes in metastatic carcinoid or VIP-secreting tumors; acromegaly
Patient support programs

Drug
Tafinlar (dabrafenib)
Indications
Patient support programs

Drug
Tasigna (nilotinib)
Indications
Ph+ chronic myeloid leukemia; adults and pediatric patients aged ≥1 year with newly diagnosed Ph+ chronic myeloid leukemia; pediatric patients aged ≥1 year with chronic Ph+ myeloid leukemia resistant or intolerant to previous tyrosine kinase inhibitor therapy
Patient support programs

Drug
Tykerb (lapatinib)
Indications
HER2/neu advanced or metastatic breast cancer
Patient support programs

Drug
Votrient (pazopanib)
Indications
Advanced renal-cell carcinoma; advanced soft-tissue sarcoma
Patient support programs

Drug
Zykadia (ceritinib)
Indications
Metastatic NSCLC with ALK mutation
Patient support programs

HR indicates hormone receptor; NSCLC, non–small-cell lung cancer; Ph+, Philadelphia chromosome–positive; TSC, tuberous sclerosis complex; VIP, vasoactive intestinal peptide.

Mekinist (trametinib) Indications

Unresectable or metastatic melanoma with BRAF V600E or V600K mutation, alone or in combination with Tafinlar; metastatic NSCLC with BRAF V600E mutation, in combination with Tafinlar; adjuvant treatment of melanoma with BRAF V600E or V600K mutations and involvement of lymph node(s) after complete resection, in combination with Tafinlar; locally advanced or metastatic anaplastic thyroid cancer with BRAF V600E mutation and no satisfactory locoregional treatment options, in combination with Tafinlar

Tafinlar (dabrafenib) Indications

Unresectable or metastatic melanoma with BRAF V600E or V600K mutation, alone or in combination with Mekinist; metastatic NSCLC with BRAF V600E mutation, in combination with Mekinist; adjuvant treatment of melanoma with BRAF V600E or V600K mutations and involvement of lymph node(s) after complete resection, in combination with Mekinist; locally advanced or metastatic anaplastic thyroid cancer with BRAF V600E mutation and no satisfactory locoregional treatment options, in combination with Mekinist; unresectable or metastatic melanoma with BRAF V600E mutation, as a single agent

Report Broken Links

Have you encountered a problem with a URL (link) on this page not working or displaying an error message?

Help us fix it! Report broken links here.

Report Broken Link

Subscribe to
Oncology Practice Management

Stay up to date with oncology news & updates by subscribing to recieve the free OPM print publications or weekly e‑Newsletter.

I'd like to recieve: